Teriparatide

Overview

Teriparatide is the recombinant form of the biologically active N-terminal 34-amino-acid fragment of human parathyroid hormone (PTH), designated PTH(1-34). Developed by Eli Lilly and marketed as Forteo, it was approved by the FDA in November 2002 for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. Teriparatide holds the distinction of being the first approved bone anabolic agent — a drug that stimulates new bone formation rather than merely slowing bone resorption.

The pharmacological principle underlying teriparatide is the "anabolic window" of parathyroid hormone. While continuous elevation of PTH (as seen in hyperparathyroidism) promotes bone catabolism and calcium mobilization, intermittent pulsatile exposure to PTH preferentially stimulates osteoblast activity and new bone formation. This paradoxical effect was recognized in the 1970s and provided the theoretical foundation for teriparatide's development as an osteoporosis therapy administered by once-daily subcutaneous injection.

Teriparatide represented a paradigm shift in osteoporosis treatment, which had previously relied exclusively on antiresorptive agents (bisphosphonates, calcitonin, estrogen, and denosumab) that slow bone loss but do not rebuild bone architecture. By directly stimulating bone formation, teriparatide can partially restore trabecular microarchitecture — a structural improvement that antiresorptive agents cannot achieve.

Treatment with teriparatide is typically limited to 2 years, after which patients transition to antiresorptive therapy to maintain the gains in bone density achieved during the anabolic phase.

Structure and Sequence

Teriparatide sequence (PTH 1-34): Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe

• Molecular formula: C₁₈₁H₂₉₁N₅₅O₅₁S₂
• Molecular weight: approximately 4,117.8 g/mol
• Production: Recombinant DNA technology using Escherichia coli expression systems
• Full-length PTH: 84 amino acids; the N-terminal 1-34 fragment retains full biological activity at the PTH1 receptor

Key structural features:

• N-terminal activation domain (residues 1-14): Essential for PTH1 receptor activation and intracellular signaling
• Receptor binding domain (residues 15-34): Mediates high-affinity binding to the extracellular domain of PTH1R
• Amphipathic helical structure: Residues 3-13 and 17-31 form alpha-helices that are critical for receptor interaction
• Met8 and Met18: Methionine residues susceptible to oxidation; oxidized forms retain partial biological activity
• No post-translational modifications required for activity, simplifying recombinant production

The 1-34 fragment was chosen for clinical development because it provides full agonist activity at the PTH1 receptor while offering simpler and more economical manufacturing compared to the full 84-amino-acid hormone.

Mechanism of Action

PTH1 Receptor Signaling

Teriparatide activates the PTH type 1 receptor (PTH1R), a class B G-protein coupled receptor expressed on osteoblasts, osteocytes, and renal tubular cells:

Intermittent vs. Continuous Exposure — The Anabolic Window:

• Intermittent (once-daily injection): Brief PTH1R activation preferentially stimulates Gs/cAMP signaling in osteoblasts, promoting:

  • Osteoblast proliferation and differentiation from mesenchymal stem cell precursors
  • Inhibition of osteoblast apoptosis, extending the lifespan of bone-forming cells
  • Increased expression of bone formation markers (osteocalcin, alkaline phosphatase, procollagen type I)
  • Upregulation of RANKL initially, followed by a sustained increase in osteoprotegerin (OPG), favoring net bone formation
  • Wnt signaling pathway activation through downregulation of sclerostin (SOST), an osteocyte-derived inhibitor of bone formation

• Continuous elevation: Sustained PTH1R activation (as in hyperparathyroidism) preferentially stimulates RANKL expression, promotes osteoclastogenesis, and results in net bone resorption — the opposite of the therapeutic effect

Bone Remodeling Effects:

• Teriparatide initially stimulates both bone formation and resorption, but formation exceeds resorption during the first 6-12 months (the "anabolic window")
• New bone is deposited on existing trabecular surfaces, improving trabecular connectivity and thickness
• Cortical bone shows increased porosity during treatment (due to activated remodeling) but net gains in cortical thickness and cross-sectional area
• After approximately 18-24 months, the formation-resorption balance equilibrates, which is one rationale for the 2-year treatment limit

Renal Effects:

• Increases renal calcium reabsorption in the distal tubule
• Increases phosphate excretion
• Stimulates 1-alpha-hydroxylase activity, increasing active vitamin D (1,25-dihydroxyvitamin D) production

Research Summary

Pharmacokinetics

• Half-life: Approximately 1 hour following subcutaneous injection
• Bioavailability: Approximately 95% after subcutaneous administration
• Time to peak: Approximately 30 minutes after subcutaneous injection; serum levels return to baseline within 3-4 hours
• Metabolism: Primarily hepatic and renal degradation through non-specific proteolytic pathways; no CYP450 involvement
• Volume of distribution: Approximately 0.12 L/kg
• Administration: 20 mcg once daily via subcutaneous injection in the thigh or abdomen; supplied in a prefilled multi-dose pen device
• Treatment duration: Maximum 2 years, based on the duration of Phase 3 trials and the osteosarcoma signal in rats
• Timing: Recommended to be administered at approximately the same time each day; may be given without regard to meals
• Storage: Refrigerated (2-8 degrees C); each pen is used for up to 28 days

Common Discussion Topics

Anabolic vs. antiresorptive sequencing: Optimal sequencing of osteoporosis therapies is a major topic in bone metabolism. Current evidence favors initiating teriparatide before transitioning to an antiresorptive agent (bisphosphonate or denosumab), as starting with bisphosphonates may blunt the anabolic response to subsequent teriparatide therapy. The VERO and DATA-Switch studies have informed sequential therapy protocols.

Osteosarcoma risk in humans: The boxed warning regarding osteosarcoma derives from rodent studies where rats exposed to high-dose teriparatide for near-lifetime durations developed bone tumors. Post-marketing surveillance spanning over two decades has not confirmed an increased osteosarcoma risk in humans at therapeutic doses and durations. The 2-year treatment limit, initially based on preclinical concern, has been extended in some guidelines, and the FDA removed the boxed warning in 2024.

Comparison to abaloparatide: Abaloparatide (Tymlos) is a synthetic analog of PTH-related peptide (PTHrP) that also acts as a bone anabolic agent through PTH1R. It may produce similar BMD gains with less hypercalcemia risk, though head-to-head comparative data remain limited.

Romosozumab comparison: Romosozumab (Evenity), a monoclonal antibody against sclerostin, offers an alternative bone anabolic mechanism. While both are anabolic agents, their mechanisms differ — teriparatide activates osteoblasts via PTH1R, while romosozumab inhibits osteocyte sclerostin that normally restrains Wnt-mediated bone formation.

Fracture healing acceleration: Preclinical and small clinical studies suggest that teriparatide accelerates fracture healing. While not an approved indication, off-label use for delayed fracture union and nonunion has been reported.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Teriparatide (Forteo) is an FDA-approved bone anabolic agent. Always consult a qualified healthcare professional.

Administration notes: Supplied as a prefilled multi-dose pen (28-day supply). Inject at approximately the same time each day. May be given without regard to meals. Store refrigerated (2-8 degrees C). Sit or lie down if orthostatic hypotension or dizziness occurs after initial doses.

Sequential therapy: After completing the 2-year course, patients should transition to an antiresorptive agent (bisphosphonate or denosumab) to maintain bone density gains.

Related Compounds

• Calcitonin — antiresorptive peptide hormone with opposing effects on osteoclasts
• BPC-157 — peptide investigated for tissue repair, though through entirely different mechanisms